GlassScriptPhysician profile
Zoe C Sherman
NPI 1730231267
$2,000.75
in general payments reported to CMS, 2019-2025
19 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $432 · 2023: $476 · 2024: $489 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.86 | 2021-2025 | |
| Astellas Pharma US INC | $255.57 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $138.20 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $130.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $127.64 | 2021-2024 | Breztri |
| Novo Nordisk INC | $124.22 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $92.06 | 2022-2023 | Quviviq |
| Dexcom, INC. | $89.07 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $75.19 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $73.57 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.37 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.88 | 2021-2023 | Livalo |
| Abbott Laboratories | $39.91 | 2023-2024 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.72 | 2021-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $27.91 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.29 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $17.09 | 2023 | Belsomra |
| Amgen INC. | $14.84 | 2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.